GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enveric Biosciences Inc (NAS:ENVB) » Definitions » Cyclically Adjusted PB Ratio

ENVB (Enveric Biosciences) Cyclically Adjusted PB Ratio : 0.00 (As of May. 27, 2025)


View and export this data going back to 1995. Start your Free Trial

What is Enveric Biosciences Cyclically Adjusted PB Ratio?

As of today (2025-05-27), Enveric Biosciences's current share price is $1.27. Enveric Biosciences's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was $4,039.38. Enveric Biosciences's Cyclically Adjusted PB Ratio for today is 0.00.

The historical rank and industry rank for Enveric Biosciences's Cyclically Adjusted PB Ratio or its related term are showing as below:

During the past years, Enveric Biosciences's highest Cyclically Adjusted PB Ratio was 3.00. The lowest was 0.01. And the median was 0.29.

ENVB's Cyclically Adjusted PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.48
* Ranked among companies with meaningful Cyclically Adjusted PB Ratio only.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Enveric Biosciences's adjusted book value per share data for the three months ended in Mar. 2025 was $1.585. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $4,039.38 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Enveric Biosciences Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Enveric Biosciences's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enveric Biosciences Cyclically Adjusted PB Ratio Chart

Enveric Biosciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.35 0.10 0.01 - -

Enveric Biosciences Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Enveric Biosciences's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Enveric Biosciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enveric Biosciences's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enveric Biosciences's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Enveric Biosciences's Cyclically Adjusted PB Ratio falls into.


;
;

Enveric Biosciences Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Enveric Biosciences's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=1.27/4039.38
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enveric Biosciences's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Enveric Biosciences's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=1.585/134.9266*134.9266
=1.585

Current CPI (Mar. 2025) = 134.9266.

Enveric Biosciences Quarterly Data

Book Value per Share CPI Adj_Book
201506 0.000 100.684 0.000
201509 0.000 100.392 0.000
201512 0.000 99.792 0.000
201603 0.000 100.470 0.000
201606 0.000 101.688 0.000
201609 0.000 101.861 0.000
201612 0.000 101.863 0.000
201703 0.000 102.862 0.000
201706 0.000 103.349 0.000
201709 0.000 104.136 0.000
201712 0.000 104.011 0.000
201803 0.000 105.290 0.000
201806 0.000 106.317 0.000
201809 0.000 106.507 0.000
201812 10,755.000 105.998 13,690.230
201903 11,158.000 107.251 14,037.333
201906 10,857.000 108.070 13,555.148
201909 13,243.000 108.329 16,494.442
201912 10,618.000 108.420 13,213.884
202003 10,219.000 108.902 12,661.120
202006 6,438.000 108.767 7,986.384
202009 6,586.000 109.815 8,092.040
202012 260.231 109.897 319.501
202103 730.462 111.754 881.923
202106 648.931 114.631 763.823
202109 1,318.262 115.734 1,536.870
202112 518.744 117.630 595.024
202203 349.171 121.301 388.393
202206 313.786 125.017 338.659
202209 164.317 125.227 177.045
202212 105.554 125.222 113.735
202303 74.863 127.348 79.318
202306 34.091 128.729 35.732
202309 16.800 129.860 17.456
202312 10.689 129.419 11.144
202403 13.337 131.776 13.656
202406 10.297 132.554 10.481
202409 6.585 133.029 6.679
202412 2.350 133.157 2.381
202503 1.585 134.927 1.585

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Enveric Biosciences  (NAS:ENVB) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Enveric Biosciences Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Enveric Biosciences's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Enveric Biosciences Business Description

Traded in Other Exchanges
N/A
Address
4851 Tamiami Trail N, Suite 200, Naples, FL, USA, 34103
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.
Executives
Frank Pasqualone director 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Kevin Michael Coveney officer: Chief Financial Officer 10 CLEVELAND ST, A, SOMERVILLE MA 02143-2606
Robert Iv Dickey officer: Chief Financial Officer 320 WEST MERMAID LANE, PHILADELPHIA PA 19118
Bevin O'neil director C/O ENVERIC BIOSCIENCES, INC.,, 4851 TAMIAMI TRAIL N, SUITE 200, NAPLES FL 34103
Michael D Webb director C/O EPIX MEDICAL INC, 71 ROGERS ST, CAMBRIDGE MA 02142
Bradley George Thompson director 1646 ACTON AVE. SW, CALGARY, ALBERTA Z4 T2T 2P9
Jillian Marie Hagel officer: Chief Technical Officer 3655 36 ST NW, CALGARY, AB Z4 T2L 1Y8
Joseph Edward Tucker director, officer: Chief Executive Officer 3655 36 ST NW, CALGARY, AB, Z4 T2L 1Y8
Peter J. Facchini officer: Chief Scientific Officer 155 RANCHRIDGE DRIVE NW, CALGARY, ALBERTA Z4 T3G 1W1
Carter Julian Ward officer: Chief Financial Officer 165 LUDLOW AVE., NORTHVALE NJ 07647
Douglas Lind director
Marcus Schabacker director ONE BAXTER PARKWAY, DEERFIELD IL 60015
Solomon Mayer director 150 CENTRAL PARK SOUTH 2ND FLOOR, NEW YORK NY 10019
David Ian Johnson director, officer: CEO and Chairman C/O ALLIQUA, INC., 850 3RD AVENUE, 18TH FLOOR, NEW YORK NY 10022
Robert G. Wilkins officer: Chief Medical Officer C/O JAY PHARMA INC., 4851 TAMIAMI TRAIL N, SUITE 200, NAPLES FL 34103

Enveric Biosciences Headlines

From GuruFocus